• Publications
  • Influence
Cross-talk between signalling pathways and the multidrug resistant protein MDR-1
The multidrug resistant protein MDR-1 has been associated with the resistance to a wide range of anti-cancer drugs. Taxol is a substrate for this transporter system and is used in the treatment of aExpand
  • 60
  • 4
Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women
Cervical scrapes from 116 British women referred with cervical cancer were tested for the presence of high oncogenic risk human papillomavirus (HPV) genotypes (HPVhr). Ninety-four per cent of theExpand
  • 129
  • 3
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.
PURPOSE In 1992, we reported the first results of a randomized study in ovarian cancer, comprising two doses of cisplatin and indicated a significant difference (P = .0008) in median survival. FourExpand
  • 132
  • 2
CERVICAL INTRAEPITHELIAL NEOPLASIA
  • 35
  • 2
The Semm cold coagulator in the management of cervical intraepithelial neoplasia.
  • I. Duncan
  • Medicine
  • Clinical obstetrics and gynecology
  • 1 December 1983
  • 36
  • 1
The Royal College of Obstetricians and Gynaecologists micro‐invasive carcinoma of the cervix study: preliminary results
Objectives To determine how micro‐invasive carcinoma of the cervix is diagnosed and treated in the United Kingdom. To record the frequency of the various pathological features which comprise theExpand
  • 33
  • 1
Mucinous ascites associated with rupture of benign ovarian teratoma. Case report
Case report A 28-year-old woman had had intermittent pain in the left iliac fossa for 2 months. There had heen no associated symptoms. She was admitted n emcrgcncy because her pain had suddenlyExpand
  • 5
  • 1
Survival after Ovarian Granulosa and Theca Cell Tumours
Ninety-two cases of ovarian granulosa and theca cell tumours were recorded in the Tayside Gynaecological Tumour Registry during the 30 year period 1948–78. A high follow-up rate was achieved throughExpand
  • 16
  • 1
The Value of Cervical Screening in Women over 50 Years of Age —Time for a Multicentre Audit
This study reviews the cervical smear history of women developing CIN aged over 50 years to consider if they might be discharged sooner from the cervical screening programme in Tayside Region. FromExpand
  • 17
  • 1
Destruction of CIN 1 and 2 with the Semm cold coagulator: 13 years' experience with a see-and-treat policy.
OBJECTIVE To assess the efficacy of the Semm Cold Coagulator (100 degrees C) for CIN 1 and 2 applying a 'see and treat' policy. DESIGN Retrospective review of women with CIN 1 and 2 seen andExpand
  • 14
  • 1